Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 4Pancreatic Intraductal Neoplasms 2

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 328Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 257lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
tocotrienol, delta × Gastrointestinal × Clear all
NCT06519097 2025-11-13

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
4 enrolled
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

NCT01450046 2016-07-07

Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01446952 2016-04-11

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00985777 2016-03-01

Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
26 enrolled
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡